NMPA approves oral formulation of Akynzeo in China
Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, and Mundipharma China Pharmaceutical, the market leader in pain management, have jointly announced that the National Medical Products Administration (NMPA) has approved the oral formulation of Akynzeo® for the treatment of chemotherapy-induced nausea and vomiting (CINV) in China.
Under the terms of the agreement, Mundipharma China Pharmaceutical has exclusive marketing, promotion and sale rights for the oral formulation of Akynzeo® in China. Helsinn will be responsible for supplying the drug to Mundipharma and co-detailing the product in Shanghai while retaining all international development rights, including clinical development activities.
Riccardo Braglia, Helsinn Group Vice Chairman and CEO commented: "Lack of control of CINV is a problem despite the availability of several antiemetics. We are pleased that Akynzeo® that targets two CINV critical pathways in a single dose will help patients and their families also in China
"We are also very pleased to be working in partnership with Mundipharma Pharmaceutical. Their expert knowledge and network in China will be invaluable as we begin to market Akynzeo® in this strategically important region."
Peter Wang, CEO of Mundipharma Pharmaceutical Greater China commented: "Today's announcement will be welcomed by Chinese cancer patients, who are undergoing chemotherapy while having to fight against CINV, as well as caregivers. It is also an important extension of Mundipharma China's portfolio. We look forward to continuing to partner with Helsinn to bring more high-quality cancer supportive care products to millions of Chinese cancer patients in the near future, in line with our vision of 'Bring more to life."
Akynzeo® capsule (300 mg netupitant/0.5 mg palonosetron) was approved on Aug 20th, 2019 in China and is indicated in adults for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, and prevention of acute and delayed nausea and vomiting associated with moderately emetogenic cancer chemotherapy.